Twist Bioscience Corporation Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
May 13 2025 - 8:00AM
Business Wire
As required by the rules of the Nasdaq Stock Market, Twist
Bioscience Corporation (NASDAQ: TWST) (“Twist” or the “Company”), a
core mid-cap growth and value equity company in the life sciences
segment of the health care sector, today announced that it has
granted a total of 72,991 equity awards, consisting of 53,600
restricted stock units (“RSUs”) and up to 19,379 performance stock
units (“PSUs”), to 36 recently hired individuals, in each case as
an inducement material to their acceptance of employment with
Twist. The employment inducement awards were granted under Twist’s
Amended and Restated Inducement Equity Incentive Plan and related
form of restricted stock unit award agreement in accordance with
Nasdaq Listing Rule 5635(c)(4).
The inducement plan is used exclusively for the grant of equity
awards to individuals who were not previously employees of Twist,
or following a bona fide period of non-employment, as an inducement
material to such individuals entering into employment with Twist,
pursuant to Nasdaq Listing Rule 5635(c)(4).
A portion of the 53,600 RSUs vest over a 48-month period for
each employee as follows: 25% vests on the one-year anniversary of
the applicable vesting commencement date (the “Vesting Commencement
Date”), and 1/16 of the RSUs vest on each quarterly anniversary (or
the last day of the month if no such day exists) of the Vesting
Commencement Date thereafter, subject to the employee’s continued
service through each vesting date. A portion of the 53,600 RSUs
vest over a 48-month period for each employee as follows: 1/16 of
the RSUs vest on each quarterly anniversary (or the last day of the
month if no such day exists) of the Vesting Commencement Date,
subject to the employee’s continued service through each vesting
date.
The up to 19,379 PSUs vest on achievement of certain performance
metrics set by the Compensation Committee of the Company’s Board of
Directors, to be achieved by no later than the end of the 2027
fiscal year (which can be earned at 50%-140% of 100% target),
subject, in each case, to the employee’s continued service through
the applicable vesting dates.
About Twist Bioscience Corporation
At Twist Bioscience, we work in service of customers who are
changing the world for the better. In fields such as medicine,
agriculture, industrial chemicals and defense, by using our
synthetic DNA tools, our customers are developing ways to better
lives and improve the sustainability of the planet. The faster our
customers succeed, the better for all of us, and Twist Bioscience
is uniquely positioned to help accelerate their efforts.
Our innovative silicon-based DNA Synthesis Platform provides
precision at a scale that is otherwise unavailable to our
customers. Our platform technologies overcome inefficiencies and
enable cost-effective, rapid, precise, high-throughput synthesis,
sequencing and therapeutics discovery, providing both the quality
and quantity of the tools they need to most rapidly realize the
opportunity ahead. For more information about our products and
services, please visit www.twistbioscience.com.
Follow us on LinkedIn | X | YouTube | Instagram | Bluesky
View source
version on businesswire.com: https://www.businesswire.com/news/home/20250513364916/en/
For Investors: Angela Bitting SVP, Corporate Affairs
925-202-6211 abitting@twistbioscience.com
For Media: Amanda Houlihan Communications Manager
774-265-5334 ahoulihan@twistbioscience.com
Twist Bioscience (NASDAQ:TWST)
Historical Stock Chart
From Jun 2025 to Jul 2025
Twist Bioscience (NASDAQ:TWST)
Historical Stock Chart
From Jul 2024 to Jul 2025